Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptor-Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance).
Hwang ES, Hyslop T, Hendrix LH, Duong S, Bedrosian I, Price E, Caudle A, Hieken T, Guenther J, Hudis CA, Winer E, Lyss AP, Dickson-Witmer D, Hoefer R, Ollila DW, Hardman T, Marks J, Chen YY, Krings G, Esserman L, Hylton N. Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptor-Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance). Journal Of Clinical Oncology 2020, 38: 1284-1292. PMID: 32125937, PMCID: PMC7164489, DOI: 10.1200/jco.19.00510.Peer-Reviewed Original ResearchConceptsER-positive DCISMagnetic resonance imagingPreoperative letrozoleEndocrine therapyDuctal carcinomaInvasive cancerH-scorePhase II single-arm studyExtended endocrine therapyMonths of letrozolePrimary endocrine therapyPrimary nonoperative treatmentPrimary end pointBreast magnetic resonance imagingCooperative group trialsSingle-arm studyER H-scoreShort-term coursePositive DCISNonoperative treatmentPostmenopausal patientsPostmenopausal womenFuture trialsStudy protocolBiomarker changes